Counsel
King & Spalding LLP
Columns
| Title | Category | Published |
|---|---|---|
| Mifepristone debate could jeopardize access to many other FDA-approved drugs | Health Care, Pharmaceuticals, Biotech, Government | May 12, 2023 |
| Title | Category | Published |
|---|---|---|
| Mifepristone debate could jeopardize access to many other FDA-approved drugs | Health Care, Pharmaceuticals, Biotech, Government | May 12, 2023 |